ArticleJournal of biosciences and medicines2026
Evaluation of Pirfenidone for the Treatment of Acute Respiratory Distress Syndrome: A Case Report.
Article in Journal of biosciences and medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Background: Acute respiratory distress syndrome (ARDS) is an aggressive, inflammatory lung injury with a high mortality rate. While accepted management includes lung protective ventilation strategies, there is currently no mainstay pharmacologic treatment for ARDS. Adjunctive pharmacologic treatment may include glucocorticoids, neuromuscular blockade and inhaled pulmonary vasodilators. Due to its anti-inflammatory, antioxidant, and anti-fibrotic properties, pirfenidone presents as a potential therapeutic option for patients with ARDS. Case Report: We present a patient treated with pirfenidone for ARDS. Our patient was a 31-year-old man who presented to the hospital with dyspnea on exertion and concern for relapsed acute myeloid leukemia. After a complex hospital course, the off-label use of pirfenidone 801 mg three times daily was pursued to treat his ARDS. The patient's ARDS resolved after 10 days of pirfenidone, with no adverse effects, and he was discharged. Conclusions: This case illustrates the potential utility of pirfenidone in the management of ARDS. After no improvement with widely accepted strategies including lung protective ventilation and steroids, the patient demonstrated recovery after the initiation of pirfenidone. We can infer correlation but not causation in this setting, prompting the need for further prospective randomized clinical trials to establish pirfenidone as a therapeutic option in ARDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.